Microphthalmia-associated transcription factor (MITF) is inducible in response to cAMP and has a pivotal role in the melanocyte-specific expression of tyrosinase for skin pigmentation. Here we suggest that the cAMP-binding site of protein kinase A (PKA) is a target in the inhibition of the melanogenic process in melanocytes, as evidenced from the molecular mechanism of small molecules such as bisabolangelone (BISA) and Rp-adenosine 3 0 ,5 0 -cyclic monophosphorothioate (Rp-cAMPS). BISA is a sesquiterpene constituent of Angelica koreana, a plant of the Umbelliferae family, whose roots are used as an alternative medicine. BISA competitively inhibited cAMP binding to the regulatory subunit of PKA and fitted into the cAMP-binding site on the crystal structure of PKA under the most energetically favorable simulation. In a-melanocyte-stimulating hormone (a-MSH)-activated melanocytes, BISA and Rp-cAMPS nullified cAMP-dependent PKA activation, dissociating catalytic subunits from an inactive holoenzyme complex. They resultantly inhibited cellular phosphorylation of the cAMP-responsive element-binding protein (CREB) or another transcription factor SOX9, thus downregulating the expression of MITF or the tyrosinase gene with decreased melanin production. Taken together, this study defined the antimelanogenic mechanism of BISA or Rp-cAMPS with a notable implication of the cAMP-binding site of PKA as a putative target ameliorating melanocyte-specific hyperpigmented disorder.
INTRODUCTION
Epidermal melanocytes synthesize melanin pigments and transfer them to keratinocytes in a complex process known as melanogenesis for skin pigmentation (Slominski et al., 2004) . Melanin pigments are produced in melanosomes, and their types are dependent on melanogenic enzymes and the availability of substrates. Tyrosinase is absolutely required in the biosynthetic pathways of black-brown eumelanins and yellow-red pheomelanins, in which it catalyzes the initial rate-limiting step, L-tyrosine to dapaquinone, through two distinct activities of tyrosine hydroxylase and dopa oxidase (Olivares and Solano, 2009 ).
In humans, second messenger cAMP has an important role in melanogenesis. a-Melanocyte-stimulating hormone (a-MSH) and other cAMP elevators, including forskolin and 3-isobutyl-1-methylxanthine, stimulate melanin production in melanocytes (Busca and Ballotti, 2000) . a-MSH specifically binds to the G protein-coupled melanocortin type I receptor, which leads to activation of adenylate cyclase (Le Pape et al., 2008) . Forskolin directly activates adenylate cyclase, and 3isobutyl-1-methylxanthine inhibits phosphodiesterase in the cAMP metabolism. Intracellular cAMP activates protein kinase A (PKA) from an inactive holoenzyme complex consisting of a regulatory subunit dimer bound to two catalytic subunits (Kim et al., 2007; Taylor et al., 2008) . Regulatory subunits of PKA have been identified as four isoforms (RIa, RIb, RIIa, and RIIb) and catalytic subunits as three isoforms (Ca, Cb, and Cg) (Brandon et al., 1997; Skalhegg and Tasken, 2000) . The regulatory isoforms possess a conserved and well-defined domain structure comprising a dimerization domain at the N-terminus, two tandem cAMP-binding sites (designated A and B) at the C-terminus, and an interconnecting linker region that docks to the active site cleft of the catalytic subunit (Diller et al., 2001; Zawadzki and Taylor, 2004) . Each regulatory isoform cooperatively binds two cAMP molecules, first to the B site followed by a second cAMP binding to the A site, which concomitantly releases the catalytic subunit, thereby allowing phosphorylation of PKA substrates such as cAMP-responsive element-binding protein (CREB) and SOX9 (Berman et al., 2005; Passeron et al., 2007; Sands and Palmer, 2008) . Phospho (p)-CREB and SOX9 are active indexes in the upregulation of microphthalmia-associated transcription factor (MITF), a basic helix-loop-helix protein crucial for melanocyte differentiation and pigmentation (Passeron et al., 2007; Liu and Fisher, 2010; Vachtenheim and Borovansky, 2010) . In turn, MITF binds to the M box containing CATGTG motifs in the promoter region of the tyrosinase gene for transcriptional activation, thereby leading to melanin biosynthesis (Kondo and Hearing, 2011) .
Beyond MITF induction, cAMP affects post-translational modification of MITF as another control point of melanogenesis. Intracellular cAMP inhibits phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT), which stimulates glycogen synthase kinase 3b (GSK3b) activity by decreasing p-GSK3b levels (Khaled et al., 2002 (Khaled et al., , 2003 . GSK3b phosphorylates the Ser-298 residue of MITF, enhancing MITF affinity to the M box for transcriptional activation of the tyrosinase gene (Khaled et al., 2002) . However, cAMP stimulates the classical mitogen-activated protein kinase pathway, in which extracellular signal-regulated kinase (ERK) phosphorylates the Ser-73 residue of MITF and ribosomal S6 kinase 1 phosphorylates the Ser-409 residue of MITF, eventually leading to proteasome-mediated MITF degradation (Englaro et al., 1995; Wu et al., 2000) .
Abnormal accumulation and biosynthesis of melanin pigments are responsible for skin disorders such as melasma, freckles, and senile lentigo (Ortonne and Passeron, 2005; Young Kang and Ortonne, 2009 ). These hyperpigmented disorders can be substantially ameliorated by treatment with arbutin or other tyrosinase inhibitors (Maeda and Fukuda, 1996; Solano et al., 2006) . Bisabolangelone (BISA, Figure 1a ) was previously identified as the major antimelanogenic constituent of Angelica koreana, a herbal medicine from the Umbelliferae family (Roh et al., 2011) . BISA inhibits a-MSHinduced melanin production in B16 melanoma cells or melana melanocytes, in which the sesquiterpene compound decreases a-MSH-inducible protein levels of tyrosinase (Roh et al., 2011) . In the current study, we aimed to elucidate a primary target of BISA for antimelanogenic activity, focusing on the tyrosinase levels in cAMP-elevated melanocytes. Indeed, BISA downregulated the expression of melanogenic genes, such as MITF and tyrosinase, by direct blockade of the cAMP binding to the PKA holoenzyme, suggesting a unique molecular target in the treatment of melanocyte-specific hyperpigmented disorder. 
RESULTS
BISA inhibits melanin production in cAMP-elevated melanocytes BISA ( Figure 1a ) and its saturated derivative 5,6-dihydro-6hydroxy-bisabolangelone (dhh-BISA, Supplementary Figure S1 online) inhibited melanin production in a-MSH-activated B16 or melan-a cell lines with similar levels of effectiveness ( Figure 1b and c), suggesting that the electrophilic moiety of BISA with an a,b-unsaturated carbonyl structure might be nonessential for its antimelanogenic action. Rp-adenosine 3 0 ,5 0 -cyclic monophosphorothioate (Rp-cAMPS; Supplementary Figure S1 online) and H-89 also inhibited a-MSHinduced melanin production in B16 cells (Figure 1b ). Rp-cAMPS is a cell-permeable cAMP antagonist inhibiting PKA activation (Dostmann et al., 1990; Wu et al., 2004) , and H-89 is a PKA inhibitor targeting the catalytic activity after dissociation from an inactive holoenzyme complex (Lochner and Moolman, 2006) . Moreover, BISA inhibited a-MSHinduced melanin production in human epidermal melanocytes originating from neonatal foreskin, as did Rp-cAMPS ( Figure 1d ). We next examined whether BISA can affect melanin production in melanocytes stimulated with other cAMP elevators including N 6 ,2 0 -O-dibutyryl (db)-cAMP as a cell-permeable cAMP-mimicking agonist. BISA inhibited db-cAMP-, forskolin-, or 3-isobutyl-1-methylxanthine-induced melanin production in B16 cells without affecting the viability of melanocytes (Supplementary Figure S2 online). To understand the in vivo efficacy of BISA, we carried out UV irradiationinduced skin pigmentation in guinea pigs, in which cAMP is also involved as a key messenger (D' Orazio and Fisher, 2011) . Dermal treatment with BISA reduced a visible pigmentation and increased a whitening index (DL value) as compared with the vehicle group (Supplementary Figure S3 online).
BISA inhibits cAMP-dependent PKA activation BISA itself did not affect the cAMP levels in a-MSH-activated B16 cells (Figure 2a ), excluding its direct effect on melanocortin type I receptor-mediated cAMP production. To elucidate a primary target for antimelanogenic activity, we tested whether BISA can affect the cAMP-induced proximal signaling event, PKA activation, by dissociating the catalytic subunit from an inactive holoenzyme complex. B16 cells were stimulated with a-MSH in the presence of BISA. Whole-cell extracts were subjected to immunoprecipitation with antisera against the regulatory subunits of PKA, such as anti-PKA (RI) and anti-PKA (RIIb), in which the anti-PKA (RI) antibody recognized the regulatory isoforms RIa and RIb of PKA. The immunoprecipitates were then probed with anti-PKA (Ca) antibody to detect the coprecipitation of the catalytic subunit. Upon exposure to a-MSH alone, PKA (Ca) was markedly dissociated from the regulatory subunits RIa/RIb or RIIb (Figure 2b B16 cells were pretreated with BISA for 2 hours and stimulated with a-melanocyte-stimulating hormone (a-MSH) for 20 minutes in the presence of BISA. (a) Cell extracts were subjected to ELISA to determine cAMP levels. In another, cell extracts were subjected to immunoprecipitation (IP) with (b) anti-PKA (RI) antibody or (c) anti-PKA (RIIb) antibody, and these IP complexes were then probed with anti-PKA (Ca) for western blot analysis (WB). (d) B16 cells were pretreated with BISA or Rp-adenosine 3 0 ,5 0 -cyclic monophosphorothioate (Rp-cAMPS) for 2 hours and stimulated with a-MSH for 30 minutes in the presence of BISA or Rp-cAMPS. Cell extracts were used for kinase assay. (e) Cell-free rhPKA with catalytic subunit only was treated with BISA, Rp-cAMPS, or H-89 for 10 minutes. PKA activity was measured by monitoring the incorporation of correlated with its kinase activity. Upon exposure to a-MSH alone, B16 cells increased the kinase activity of PKA ( Figure 2d ). BISA inhibited a-MSH-induced PKA activity in cells, in which Rp-cAMPS was also effective (Figure 2d ). To understand whether BISA can directly interact with the catalytic subunit of PKA, we determined the in vitro kinase activity of PKA with the catalytic subunit only. BISA or Rp-cAMPS did not affect the catalytic subunit-mediated kinase activity of PKA in cell-free reactions, but H-89 inhibited directly (Figure 2e ). Therefore, BISA can inhibit a-MSH-induced PKA activation, whose mechanism of action is similar to that of Rp-cAMPS as a PKA-directed cAMP antagonist (Le Pape et al., 2008) . from the complexes with RIIb. This mechanism of action was reversible because the fluorescence intensity was recovered in the pretreatment with BISA followed by competitive titration with excess 8-[j-575]-cAMP (Supplementary Figure S4 online) . Moreover, dhh-BISA and Rp-cAMPS inhibited 8-[j-575]-cAMP binding to RIIb (Figure 3b ). However, BISA or dhh-BISA did not affect the basal fluorescence spectra of 8-[j-575]-cAMP in the absence of RIIb (data not shown).
On the basis of the evidence that BISA competitively inhibited 8-[j-575]-cAMP binding to the regulatory subunit RIIb of PKA as well as a-MSH-induced PKA activation by blocking the dissociation of the catalytic subunit from regulatory subunits (RIa/RIb, and RIIb), we proposed a docking model of BISA to the crystal structure of RIIb of PKA (Diller et al., 2001; Zawadzki and Taylor, 2004) . BISA was well fitted into the cAMP-binding A site of RIIb with close contacts to Ile-180, Tyr-213, Gly-220, Glu-221, and Arg-230 residues under the most energetically favorable simulation ( Figure 4a ). Hydrogen bonds could be achieved between the hydroxyl group at C-3 of BISA and either side chain of Tyr-231 or Glu-221 and between the ketone group at C-4 of BISA and the peptidyl amino backbone of Glu-221 ( Figure 4a ). Similarly, BISA was also docked to the cAMP-binding B site of RIIb with 
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Glu-221 cAMP-binding A site cAMP-binding B site close contacts to Glu-350, Leu-351, Arg-359, Ala-360, and Tyr-397 residues (Figure 4b ). Hydrogen bonds could be achieved between the hydroxyl group at C-3 of BISA and either side chain of Glu-350 or Tyr-397 and between the ketone group at C-4 of BISA and the peptidyl amino backbone of Leu-351 ( Figure 4b) . Moreover, the BISA-docking simulations overlapped with those of the ligand cAMP ( Supplementary Figure S5 online) .
BISA inhibits CREB activation and SOX9 induction in melanocytes
As BISA inhibited a-MSH-induced PKA activation by blocking cAMP binding to the regulatory subunit of PKA, we tested whether BISA can affect downstream signal cascades in the melanogenic process. Upon exposure to the cAMP elevator a-MSH or db-cAMP alone, B16 or melan-a cells markedly increased the Ser-133 phosphorylation of CREB, in which the anti-p-CREB antibody also recognized the phosphorylated form of activating transcription factor-1 (p-ATF-1) (Figure 5a and b) . p-ATF-1 is closely related to p-CREB in structure and function (Hummler et al., 1994) . BISA inhibited the CREB phosphorylation in a-MSH-activated B16 cells or db-cAMP-activated melan-a cells (Figure 5a and b) . Rp-cAMPS and H-89 also inhibited db-cAMP-induced CREB phosphorylation in melan-a cells (Figure 5b ). We next transfected B16 cells with the CRE-Luc construct, a luciferase reporter gene fused to three copies of the CREB-responsive CRE motif, and then stimulated with a-MSH in the presence of BISA. Upon exposure to a-MSH alone, the transfected cells increased luciferase expression, reporting CREB transcriptional activity up to about 10-fold over basal levels (Figure 5c ). BISA inhibited a-MSH-induced CREB transcriptional activity in the cells (Figure 5c ). PKA also phosphorylates SOX9 in cAMP-elevated melanocytes, and CREB transcriptional activity upregulates the expression of the SOX9 gene (Passeron et al., 2007; Piera-Velazquez et al., 2007) . Upon exposure to a-MSH alone, B16 cells significantly increased the Ser-181 phosphorylation of SOX9 (Figure 5d ). BISA inhibited a-MSH-induced SOX9 phosphorylation at an early time point (Figure 5d ) and also decreased cellular induction of SOX9 in delayed kinetics (Figure 5e ).
BISA and Rp-cAMPS suppress the a-MSH-induced expression of MITF or the tyrosinase gene CREB-responsive CRE motif and SOX9-binding DNA consensus appear to be essential for maximal MITF induction in cAMPelevated melanocytes, even though the MITF promoter contains several cis-acting elements (Udono et al., 2000; Passeron et al., 2007) . Upon exposure to a-MSH alone, B16 cells markedly increased the protein levels of phosphorylated and nonphosphorylated MITFs (Figure 6a ). BISA decreased a-MSH-inducible protein levels of MITFs in cells, as did Rp-cAMPS ( Figure 6a ). Accordingly, BISA attenuated a-MSH-induced messenger RNA (mRNA) levels of MITF, in which Rp-cAMPS and H-89 were also effective ( Figure 6b ). Moreover, BISA and Rp-cAMPS inhibited a-MSH-increased promoter activity of the MITF gene (Figure 6c ), as determined using B16 cells transfected with the MITF-Luc construct, a luciferase reporter containing MITF promoter ( À 2,200/ þ 95) (Udono et al., 2000) . Second messenger cAMP also affects post-translational modification of MITF, which is differently regulated from CREB-or SOX9-mediated MITF induction in the melanogenic pathways (Englaro et al., 1995; Khaled et al., 2002 Khaled et al., , 2003 . Upon exposure to a-MSH or PI3K inhibitor (wortmannin, LY294002) alone, B16 cells decreased p-GSK3b levels with the concomitant induction of tyrosinase mRNA (Supplementary Figure S6a or PI3K inhibitor-decreased p-GSK3b levels, but it consistently attenuated the a-MSH-induced mRNA levels of tyrosinase without affecting the PI3K inhibitor-induced tyrosinase expression ( Supplementary Figure S6a online ). However, SB216763 as an inhibitor of GSK3b activity suppressed not only a-MSH-induced but also PI3K inhibitor-induced mRNA levels of tyrosinase ( Supplementary Figure S6a online) . In another, cAMP activates ERK-1/2 and then ribosomal S6 kinase 1, which phosphorylates MITF proteins marking for the proteasome-mediated MITF degradation (Englaro et al., 1995; Wu et al., 2000) . Upon exposure to a-MSH alone, B16 cells phosphorylated ERK-1/2 and increased the mRNA levels of MITF ( Supplementary Figure S6b online) . BISA did not affect a-MSHincreased p-ERK-1/2 levels in the cells but still suppressed the mRNA levels of MITF ( Supplementary Figure S6b online) . Treatment with MEKK inhibitor PD98059 or U0126 decreased a-MSH-induced ERK-1/2 phosphorylation without affecting the mRNA levels of MITF ( Supplementary Figure S6b online) . Therefore, BISA can suppress MITF induction in cAMP-elevated melanocytes but not affect the PI3K/GSK3b or MEKK/ERK-1/2 pathway, conferring post-translational modification of MITF. BISA decreases a-MSH-induced protein levels of tyrosinase in melanocytes for antimelanogenic activity (Roh et al., 2011) . In the current study, BISA suppressed a-MSHor db-cAMPinduced protein levels of tyrosinase in B16 or melan-a cells, in which dhh-BISA and Rp-cAMPS were also effective (Supplementary Figure S7a and b online) . Accordingly, BISA attenuated a-MSH-induced mRNA levels of tyrosinase in B16 cells and also in melan-a cells, as did Rp-cAMPS and H-89 ( Supplementary Figure S7c and d online) . Moreover, BISA inhibited a-MSH-increased promoter activity of the tyrosinase gene ( Supplementary Figure S7e online) , as determined using B16 cells transfected with the tyrosinase-Luc construct, a luciferase reporter containing tyrosinase promoter ( À 2,236/ þ 59) (Bertolotto et al., 1996) . These results indicate that BISA can downregulate the cAMP-induced expression of tyrosinase gene at the transcription level.
DISCUSSION
cAMP is a key messenger in the melanogenic process, in which the activation of PKA or CREB leads to upregulation of MITF and tyrosinase genes. BISA and other sesquiterpene compounds (a-bisabolol, 2,3-epoxyjuanislamin, parthenolide, and torillin) suppress the expression of the tyrosinase gene for antimelanogenic activity in cAMP-elevated melanocytes Ohguchi et al., 2009; Yun et al., 2009; Roh et al., 2011) . However, their primary targets are largely unknown. In particular, a-bisabolol decreases intracellular cAMP levels requisite for CREB activation, which in turn downregulates the expression of the MITF or tyrosinase gene . Moreover, a-bisabolol reduces UV irradiation-induced skin pigmentation of Asian women (Lee et al., 2010) . In the current study, BISA did not affect the cAMP levels in a-MSH-activated melanocytes but inhibited cAMP-induced PKA activation in cells. BISA specifically targeted the cAMP-binding site of PKA, as evidenced by its competitive displacement of 8-[j-575]-cAMP bound to the regulatory subunit RIIb of PKA and its inhibitory action on the a-MSH-induced dissociation of catalytic PKA from an inactive holoenzyme complex. Accordingly, BISA fitted well into the cAMP-binding A and B sites on the crystal structure of PKA under the most energetically favorable simulation. This unique mechanism of BISA affected PKA activitymediated CREB or SOX9 activation in cAMP-elevated B16 or melan-a cells, thus suppressing the transcription of the MITF or tyrosinase gene in the melanogenic pathway ( Supplementary  Figure S8 online) . However, BISA did not directly affect the kinase activity of PKA with the catalytic subunit only, nor the post-translational modification of MITF through the PI3K/GSK3b and MEKK/ERK pathways in melanogenesis.
The PKA inhibitors for which a mechanism of action is known can be divided into two general groups: (i) cAMP antagonists targeting the regulatory subunit of the inactive holoenzyme complex, and (ii) competitive inhibitors targeting the protein substrate-or cofactor ATP-binding site of the catalytic subunit after dissociation from the inactive holoenzyme complex. Rp-cAMPS is a PKA-directed cAMP antagonist, preventing the dissociation and activation of the inactive holoenzyme complex (Dostmann et al., 1990; Wu et al., 2004) . In the current study, we report that Rp-cAMPS suppressed the expression of the MITF or tyrosinase gene and inhibited melanin production in cAMP-elevated melanocytes. Therefore, BISA mimicked Rp-cAMP in the antimelanogenic mechanism, even though the chemical structure of BISA is not related to those of the agonist cAMP and the antagonist Rp-cAMPS. Peptide PKI and chemical H-89 are typical PKA inhibitors that target the catalytic subunit after dissociation from an inactive holoenzyme complex (Knighton et al., 1991; Engh et al., 1996; Lochner and Moolman, 2006; Zimmermann et al., 2008) , thus acting on one step later than the reference of Rp-cAMPS or BISA. PKI is expressed in a variety of tissues and inhibits the kinase activity of PKA after binding to the catalytic site as a pseudosubstrate (Knighton et al., 1991; Zimmermann et al., 2008) . PKI has another domain structure that allows it to export the catalytic subunit of PKA from the nucleus to the cytoplasm (Knighton et al., 1991; Zimmermann et al., 2008) , where catalytic PKA can be converted to the inactive holoenzyme complex upon reassociation with regulatory subunits. However, the antimelanogenic activity of PKI has not been defined yet. H-89 binds to the ATP-binding site of PKA with the catalytic subunit only and inhibits the kinase activity of PKA in a competitive manner with respect to the cofactor ATP (Engh et al., 1996; Lochner and Moolman, 2006) . As ATP exists at millimolar levels inside most cells, H-89 should be used at much higher concentrations to inhibit the cellular activity of PKA than in cell-free assays. H-89 also inhibits several protein kinases (MSK1, S6K1, ROCK II) with a potency similar to or greater than that of PKA (Davies et al., 2000) . Therefore, H-89 is a nonspecific inhibitor of PKA activity. In the current study, H-89 inhibited PKA activity-mediated CREB activation in cAMP-elevated melanocytes and resultantly downregulated the expression of the MITF or the tyrosinase gene. However, another cAMP/PKA-independent mechanism is also suggested for the antimelanogenic activity of H-89 (Cheli et al., 2009) .
BISA exerts several pharmacological activities, including antiinflammatory action by inhibition of NF-kB or AP1 activation in macrophages, antiulcer effects in animal models induced by ethanol or Pylorus ligation, and acaricidal effects against Dermatophagoides farinae or D. pteronyssinus (Kang et al., 2006; Wang et al., 2009; Jung et al., 2010) . The molecular bases for these bioactivities might be attributable in part to the primary target of BISA, that is, cAMP-dependent PKA activation, as determined in this study, as PKA is often activated by extracellular stressors or various specific receptors, and its downstream substrate CREB can affect the expression of many genes containing conserved CRE elements adjacent to the TATA boxes (Zhang et al., 2005; Sands and Palmer, 2008; Taylor et al., 2008) .
In conclusion, the cAMP-binding site of PKA is a target of BISA in the suppression of the MITF or the tyrosinase gene. This mechanism of action had not been previously assigned to any antimelanogenic chemicals/peptides, not even to Rp-cAMPS with respect to melanocyte pigmentation. Finally, this study suggests a therapeutic target against melanocytespecific hyperpigmented disorder, as evidenced from the molecular basis of BISA or Rp-cAMPS in the inhibition of the cAMP-induced melanogenic pathway.
MATERIALS AND METHODS

Materials
BISA was isolated from the dried roots of A. koreana as described previously (Roh et al., 2011) , and its purity (497%) was measured by HPLC analysis (Supplementary Figure S9 online) . Primary and secondary antibodies used in this study were purchased from Abcam (Cambridge, UK), Santa Cruz Biotech (Santa Cruz, CA) or Cell Signaling Tech (Danver, MA). PKA (RIIb) polypeptides were purchased from Proteintech group (Chicago, IL), and 8-[j-575]-cAMP from BioLog (Bremen, Germany). All other chemicals including a-MSH were otherwise purchased from Sigma-Aldrich (St Louis, MO).
Melanin quantification
Melanocytes were stimulated with a-MSH (100 nM), db-cAMP (3 mM), forskolin (10 mM), or IBMX (100 mM) for 3-6 days. The cells were counted and then disrupted in 0.85 N NaOH and 20% DMSO with heating at 80 1C. Absorbance values were measured at 405 nm with synthetic melanin as a standard, and then normalized to the cell numbers.
cAMP quantification B16 cells were stimulated with a-MSH (100 nM) for 20 minutes. Cell extracts were used to determine cAMP levels using an ELISA kit (R&D Systems, Minneapolis, MN).
Immunoprecipitation
Cell extracts were incubated overnight with anti-PKA (RI) or anti-PKA (RIIb) antibody (2 mg), and then precipitated with protein G-sepharose beads at 4 1C for 3 hours.
PKA/Kemptide assay
Enzyme sources were incubated with a mixture of 83 mM Kemptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly), 20 mM MOPS (pH 7.2), 13 mM MgCl 2 , 150 mM KCl, 100 mM ATP, and 10 mCi [g-32 P]ATP at 30 1C for 20 minutes. Aliquots of the reaction mixture were spotted onto P81 phosphocellulose papers, and then washed three times with 0.75% phosphoric acid followed by one wash with 100% acetone. Radioactivities on the papers were measured using a liquid scintillation counter.
Displacement assay of 8-[u-575]-cAMP
Fluorescent 8-[j-575]-cAMP (3 mM) was incubated with cell-free RIIb polypeptide of PKA (1 mg À 1 ml) for 3 hours to reach stable fluorescence values under excitation at 575 nm. Non-fluorescent BISA was then treated for 2 hours, and followed by measuring relative fluorescence units emitted at 590-650 nm.
Molecular modeling
Docking simulations were carried out with the Glide program, and the crystal structure of regulatory subunit RIIb of PKA was cited from Protein Data Bank (1CX4). The receptor grid files were generated with van der Waals scaling of the receptor at 1.0 at the center of the cAMP-binding A or B site of PKA. The lowest energy conformation was evaluated by the Glide docking score.
Statistical analysis
Data are expressed as mean ± SD of at least three separate experiments after the one-way analyses of variance followed by the Dunnett's test. Values of Po0.05 were considered as significantly different.
